8-K Announcements
6Material company update
Nov 13, 2025·SEC
Material company update
Nov 10, 2025·SEC
Material company update
Nov 6, 2025·SEC
Metsera, Inc.(MTSR)Earnings, Financials & Key Ratios
MTSR•NASDAQ
$70.50
Price updated Jun 20, 2026
AboutMetsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$225M-414.8%
- Net Income-$209M-343.0%
- EPS (Diluted)-2.03-113.7%
- ROE-108.4%-126.2%
MTSR Price & Volume
Metsera, Inc. (MTSR) stock price & volume — 10-year historical chart
Loading chart...
Accelerating Clinical Investment Drives Significant Cash Burn
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Clinical trial execution failure
Key Thesis Takeaways
- Metsera is currently in a high-intensity development phase, prioritizing the advancement of its NuSH platform over near-term profitability.
- While the company maintains a current ratio of 4.25, the rapid escalation of R&D spending to $63.7 million in 2025Q3 suggests a narrowing runway that may necessitate future capital raises.
- Investors should monitor the clinical trial outcomes closely, as the current $116.2 million quarterly net loss reflects the substantial financial commitment required to bring its metabolic therapeutic pipeline to market.
Verdict Logic
the company's accelerating cash burn, which reached an $81.7 million operating outflow in 2025Q3, presents significant dilution risk for shareholders in the absence of near-term revenue generation.
MTSR Growth Metrics
Metsera, Inc. (MTSR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-56.92%
5 Years-56.92%
3 Years-56.92%
Last Year-84.47%
MTSR Recent Earnings
Metsera, Inc. (MTSR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 0/4 qtrs (0%)
Q4 2025Latest
Nov 12, 2025Metric
Actual
Est
EPS
$1.11-98.2%
$0.56
Rev
—
—
Q3 2025
Jul 28, 2025Metric
Actual
Est
EPS
$0.66-0.3%
$0.66
Rev
—
—
Q2 2025
May 12, 2025Metric
Actual
Est
EPS
$1.03-21.2%
$0.85
Rev
—
—
Q2 2025
Mar 26, 2025Metric
Actual
Est
EPS
$3.52-340.0%
$0.80
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 12, 2025 | $1.11vs $0.56-98.2% | — |
| Q3 2025 | Jul 28, 2025 | $0.66vs $0.66-0.3% | — |
| Q2 2025 | May 12, 2025 | $1.03vs $0.85-21.2% | — |
| Q2 2025 | Mar 26, 2025 | $3.52vs $0.80-340.0% | — |
Based on last 4 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Metsera, Inc. (MTSR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $70.50 | $7.43B | -34.73 | — | — | -108.4% | — | |
| $42.13 | $4.88B | -13.21 | — | — | -71.31% | — | |
| $52.95 | $4.77B | -51.41 | — | — | -20.02% | — | |
| $56.63 | $3.26B | -23.60 | — | — | -15.14% | — | |
| $2.05 | $141.8M | -0.97 | — | — | -59.89% | — | |
| $49.64 | $220.59B | 14.10 | 6.43% | 37.2% | 66.36% | — |
Compare MTSR vs Peers
Metsera, Inc. (MTSR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MTSR SEC Filings & Documents
Metsera, Inc. (MTSR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when MTSR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MTSR Frequently Asked Questions
Metsera, Inc. (MTSR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is MTSR profitable?
Metsera, Inc. (MTSR) reported a net loss of $314.4M for fiscal year 2024.
Dividend & Returns
What is MTSR's return on equity?
Metsera, Inc. (MTSR) has a return on equity (ROE) of -108.4%. Negative ROE indicates the company is unprofitable.
What is Metsera, Inc.'s free cash flow?
Metsera, Inc. (MTSR) had negative free cash flow of $231.6M in fiscal year 2024, likely due to heavy capital investments.